Trial Profile
A Multicenter, Open Label, Interventional, Prospective, Non Randomized, One Cohort Extension Study To Assess the Sustainability of the Effect of NOVA22007 Following Treatment Discontinuation in Improved Patients With Severe Dry Eye Disease (DED)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 30 Nov 2018
Price :
$35
*
At a glance
- Drugs Ciclosporin (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Sponsors Santen S.A.S.
- 30 Oct 2018 Results published in the Clinical Therapeutics
- 06 Nov 2014 New trial record